We have shown that human B-cell non-Hodgkin lymphomas (B-NHLs) express heat shock protein (HSP)H1/105 in function of their aggressiveness. Here, we now clarify its role as a functional B-NHL target by testing the hypothesis that it promotes the stabilization of key lymphoma oncoproteins. HSPH1 silencing in 4 models of aggressive B-NHLs was paralleled by Bcl-6 and c-Myc downregulation. In vitro and in vivo analysis of HSPH1-silenced Namalwa cells showed that this effect was associated with a significant growth delay and the loss of tumorigenicity when 10(4) cells were injected into mice. Interestingly, we found that HSPH1 physically interacts with c-Myc and Bcl-6 in both Namalwa cells and primary aggressive B-NHLs. Accordingly, expression of HSPH1 and either c-Myc or Bcl-6 positively correlated in these diseases. Our study indicates that HSPH1 concurrently favors the expression of 2 key lymphoma oncoproteins, thus confirming its candidacy as a valuable therapeutic target of aggressive B-NHLs.

HSP105 inhibition hampers the growth of human aggressive B-cell non-Hodgkin lymphoma by counteracting key oncogenic pathways / R. Zappasodi, A. Cavané, M. Tortoreto, C. Tringali, A.D. Cabras, G. Ruggiero, L. Castagnoli, B. Venerando, N. Zaffaroni, S.M. Pupa, A.M. Gianni, M. Di Nicola. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - 48:Suppl. 2(2013), pp. S431-S432. (Intervento presentato al 39. convegno Annual Meeting of the European Group for Blood and Marrow Transplantation tenutosi a London nel 2013) [10.1038/bmt.2013.23].

HSP105 inhibition hampers the growth of human aggressive B-cell non-Hodgkin lymphoma by counteracting key oncogenic pathways

A. Cavané
Secondo
;
C. Tringali;B. Venerando;A.M. Gianni
Penultimo
;
2013

Abstract

We have shown that human B-cell non-Hodgkin lymphomas (B-NHLs) express heat shock protein (HSP)H1/105 in function of their aggressiveness. Here, we now clarify its role as a functional B-NHL target by testing the hypothesis that it promotes the stabilization of key lymphoma oncoproteins. HSPH1 silencing in 4 models of aggressive B-NHLs was paralleled by Bcl-6 and c-Myc downregulation. In vitro and in vivo analysis of HSPH1-silenced Namalwa cells showed that this effect was associated with a significant growth delay and the loss of tumorigenicity when 10(4) cells were injected into mice. Interestingly, we found that HSPH1 physically interacts with c-Myc and Bcl-6 in both Namalwa cells and primary aggressive B-NHLs. Accordingly, expression of HSPH1 and either c-Myc or Bcl-6 positively correlated in these diseases. Our study indicates that HSPH1 concurrently favors the expression of 2 key lymphoma oncoproteins, thus confirming its candidacy as a valuable therapeutic target of aggressive B-NHLs.
Settore BIO/10 - Biochimica
Settore BIO/12 - Biochimica Clinica e Biologia Molecolare Clinica
2013
Article (author)
File in questo prodotto:
File Dimensione Formato  
bmt201323a.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 95.66 MB
Formato Adobe PDF
95.66 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/225186
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact